Kyntheum improves psoriasis on the nail, AAD presentation shows

Danish dermatology specialist LEO Pharma has presented new data on its already-marketed psoriasis drug Kyntheum (brodalumab) at the 76th annual American Academy of Dermatology (AAD) meeting in San Diego, California, USA.

These data demonstrated long-term improvements in psoriasis on the nail with Kyntheumwhen compared to placebo or ustekinumab. Psoriasis on the nail, which is challenging to treat, affects around half of the estimated 125 million people living with psoriasis worldwide.

The efficacy of Kyntheum in psoriasis on the nail (as measured by NAPSI, the nail psoriasis severity index) as assessed based on the outcomes of two randomised Phase III clinical studies, AMAGINE-2 and -3. Results showed that in patients with psoriasis on the nail, Kyntheum decreased the NAPSI score in the most affected nail at week 52 and was associated with a lower NAPSI score than ustekinumab and placebo. Patients continuously receiving Kyntheum 210mg changed from a mean NAPSI score of 9.6 at baseline to 1.6 at week 52; patients receiving ustekinumab changed from a mean NAPSI score of 9.9 at baseline to 2.4 at week 52. Across all patients, the profile of treatment-emergent adverse events was similar in those taking Kyntheum 210 mg and ustekinumab.